Abstract
Disease manifestations with Aspergillus spp. are very diverse and dependent on interaction between the fungus and the host. Invasive aspergillosis (IA) is the most severe form of Aspergillus - associated disease found in immunocompromised hosts. Infections are mainly due to Aspergillus (A.) fumigatus, an air-borne opportunistic pathogen that causes 90% of IA. Mortality rate of this disease is still very high (50-95%), partly because of diagnostic difficulties, limited antifungal treatment options, weak conditions of patients at risk; but also in part because understanding of virulence factors involved in A. fumigatus pathogenicity and interactions of the pathogen with the host immune system is still poor. This review focuses on properties of A. fumigatus in terms of putative virulence factors and interactions of the pathogen with a main focus on the innate immune system.
Keywords: Invasive aspergillosis, virulence, pathogenicity factors, classification of IA, innate immune response.
Current Pharmaceutical Design
Title:New Insights into Invasive Aspergillosis - from the Pathogen to the Disease
Volume: 19 Issue: 20
Author(s): Ulrike Binder and Cornelia Lass-Florl
Affiliation:
Keywords: Invasive aspergillosis, virulence, pathogenicity factors, classification of IA, innate immune response.
Abstract: Disease manifestations with Aspergillus spp. are very diverse and dependent on interaction between the fungus and the host. Invasive aspergillosis (IA) is the most severe form of Aspergillus - associated disease found in immunocompromised hosts. Infections are mainly due to Aspergillus (A.) fumigatus, an air-borne opportunistic pathogen that causes 90% of IA. Mortality rate of this disease is still very high (50-95%), partly because of diagnostic difficulties, limited antifungal treatment options, weak conditions of patients at risk; but also in part because understanding of virulence factors involved in A. fumigatus pathogenicity and interactions of the pathogen with the host immune system is still poor. This review focuses on properties of A. fumigatus in terms of putative virulence factors and interactions of the pathogen with a main focus on the innate immune system.
Export Options
About this article
Cite this article as:
Binder Ulrike and Lass-Florl Cornelia, New Insights into Invasive Aspergillosis - from the Pathogen to the Disease, Current Pharmaceutical Design 2013; 19 (20) . https://dx.doi.org/10.2174/13816128113199990366
DOI https://dx.doi.org/10.2174/13816128113199990366 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
CRISPR-Cas9, A Promising Therapeutic Tool for Cancer Therapy: A Review
Protein & Peptide Letters VEGF Inhibitors in Metastatic Renal Cell Carcinoma: Current Therapies and Future Perspectives
Current Clinical Pharmacology Recognition and Function of HumanγδT Cells: Application for Tumor Immunotherapy
Current Immunology Reviews (Discontinued) Modulation of TRAIL-Induced Apoptosis by HDAC Inhibitors
Current Cancer Drug Targets Clinical Studies with Bismuth-213 and Actinium-225 for Hematologic Malignancies
Current Radiopharmaceuticals Fetuin-A: A Multifunctional Protein
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Review: The JAK/STAT Protein Activation – Role in Cancer Development and Targeted Therapy
Current Signal Transduction Therapy Cyclin Dependent Kinase 1 Inhibitors: A Review of Recent Progress
Current Medicinal Chemistry Global Gene Expression in Classification, Pathogenetic Understanding and Identification of Therapeutic Targets in Acute Myeloid Leukemia
Current Pharmaceutical Biotechnology Safety of Systemic Biologic Agents in the Treatment of Non-malignant Skin Disorders
Current Drug Safety Triterpenoids for Cancer Prevention and Treatment: Current Status and Future Prospects
Current Pharmaceutical Biotechnology Artificial O2 Carriers: Status in 2005
Current Pharmaceutical Design Distinct Functions of Retinoic Acid Receptor Beta Isoforms: Implications for Targeted Therapy
Endocrine, Metabolic & Immune Disorders - Drug Targets The Histone Deacetylase Inhibitor, MS-275 (Entinostat), Downregulates c-FLIP, Sensitizes Osteosarcoma Cells to FasL, and Induces the Regression of Osteosarcoma Lung Metastases
Current Cancer Drug Targets Combined Modality Therapy in Pancreatic Adenocarcinoma: Review and Updates on a Controversial Issue
Current Pharmaceutical Design Circulating Tumor Stem Cells as Biomarkers for Cancer Progression
Recent Patents on Biomarkers Different Aspects of Head and Neck Squamous Cell Carcinoma: Cancer Stem Cells, their Niche and Targeted Therapy
Current Stem Cell Research & Therapy Delivery of Nanoparticles for Treatment of Brain Tumor
Current Drug Metabolism Radionuclide Liver Cancer Therapies: From Concept to Current Clinical Status
Anti-Cancer Agents in Medicinal Chemistry Nitrogen-Containing Heterocycles as Anticancer Agents: An Overview
Anti-Cancer Agents in Medicinal Chemistry